Robert A. Balk

TL;DR: Primary and retrospective analyses of efficacy suggest that treatment with rhIL-1ra results in a dose-related increase in survival time among patients with sepsis who have organ dysfunction and/or a predicted risk of mortality of 24% or greater.

TL;DR: There was no decrease in mortality between placebo and TNF-α MAb in all infused patients, and in septic shock patients who received T NF- α MAb, a significant reduction in mortality was present 3 days after infusion; however, although a trend toward reduced mortality continued at 28 days following treatment with TTFMAb, the difference in mortality among shock patients treated with placebo or TFB was not significant.

TL;DR: The sepsis syndrome represents a systemic response to infection and is defined as hypothermia or hyperthermia, tachycardia, tachypnea, clinical evidence of an infection site and with at least one end-organ demonstrating inadequate perfusion or dysfunction expressed as poor or altered cerebral function.

TL;DR: In this article, the authors evaluated the therapeutic efficacy and safety of recombinant human interleukin-1 receptor antagonist (rhlL-1ra) in the treatment of patients with severe sepsis.